Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 193Carcinoma, Non-Small-Cell Lung 160Ovarian Neoplasms 96Lung Neoplasms 58Fallopian Tube Neoplasms 57Neoplasms 50Triple Negative Breast Neoplasms 36Neoplasm Metastasis 36Esophageal Neoplasms 22Carcinoma, Ovarian Epithelial 22Parkinson Disease 4, Autosomal Dominant Lewy Body 21Stomach Neoplasms 20Squamous Cell Carcinoma of Head and Neck 20Head and Neck Neoplasms 19Endometrial Neoplasms 19Adenocarcinoma of Lung 17Melanoma 15Breast Neoplasms, Male 15Urinary Bladder Neoplasms 13Carcinoma 12Uterine Cervical Neoplasms 11Recurrence 11Carcinoma, Squamous Cell 11Brenner Tumor 11Adenocarcinoma Of Esophagus 10Small Cell Lung Carcinoma 9Peritoneal Neoplasms 9Esophageal Squamous Cell Carcinoma 9Adenocarcinoma, Bronchiolo-Alveolar 9Prostatic Neoplasms 8

Interventions

cobimetinib 1atezolizumab 1Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma, Mucinous × Paclitaxel × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡